Avastin

AVASTIN INEFFECTIVE: The Food and Drug Administration said Thursday the best-selling cancer drug Avastin should no longer be used in breast cancer patients after failing to extend or improve patient lives in several studies.

SFGate: Top News Stories By The Associated Press 2010

The study compared Genentech's Lucentis, which costs about $2,000 per treatment, with a similar drug from the company called Avastin, which isn't approved for the eye but costs only about $50 per eye treatment.

Genentech Fights the Use of Its Own Cheaper Drug Alicia Mundy 2011

Yet when Ms. Satossky concludes that Avastin is lifesaving and cost is irrelevant, she is confronted with scientific and economic evaluations that have the potential to override her "empowerment" and deny her treatment.

We Tell Patients to Be Empowered 2010

Avastin is an angiogenesis inhibitor, a class of cancer drugs that have not lived up to their hype: although they stop one mechanism by which malignant cells grow blood vessels to sustain them, the cells often activate a different mechanism and go on proliferating.

It’s Not About Rationing 2010

Because the actual cost of producing Avastin is a fraction of what Genentech charges for it, some analysts and doctors had expected the company to lower Avastin's price per milligram for use in lung and breast cancer.

Double Drug Jeopardy Nick Anthis 2006

Surely this steep price tag must mean that Avastin is just a really expensive drug to produce, or maybe Genentech just wants to recoup the money it spent to develop it.

Archive 2006-02-01 Nick Anthis 2006

Because the actual cost of producing Avastin is a fraction of what Genentech charges for it, some analysts and doctors had expected the company to lower Avastin's price per milligram for use in lung and breast cancer.

Archive 2006-02-01 Nick Anthis 2006

Surely this steep price tag must mean that Avastin is just a really expensive drug to produce, or maybe Genentech just wants to recoup the money it spent to develop it.

Double Drug Jeopardy Nick Anthis 2006

"While we do see risk to some of the more aggressive near-term Avastin estimates, we continue to expect this drug to be a mega blockbuster, and would caution against aggressive selling from a few slower quarters prior to FDA label expansion and broader reimbursement."

Genentech's Avastin Sales Slow For Breast, Lung Cancer 2006

"While we do see risk to some of the more aggressive near-term Avastin estimates, we continue to expect this drug to be a mega blockbuster, and would caution against aggressive selling from a few slower quarters prior to FDA label expansion and broader reimbursement."

Biotechs Start 2006 With Big Gains 2006